Business Context and Reporting Period
This Form 6-K filing covers the period ended April 6, 2004, for GlaxoSmithKline plc and its subsidiaries, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. The report serves to incorporate by reference exhibits related to a debt issuance into a pending Registration Statement on Form F-3.
Key Financial Metrics
The filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The document focuses exclusively on the terms of new debt instruments.
| Instrument | Issuer | Coupon Rate | Maturity |
|---|---|---|---|
| Notes | GSK Capital plc | 2.375% | 2007 |
| Notes | GSK Capital Inc. | 4.375% | 2014 |
| Notes | GSK Capital Inc. | 5.375% | 2034 |
All notes are guaranteed by GlaxoSmithKline plc.
Material Changes
The filing does not report material changes to the company's business operations or financial position compared to prior periods. The primary change is the execution of underwriting agreements and indentures dated March 30, 2004, and April 6, 2004, respectively, to facilitate the issuance of the notes listed above.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a procedural filing to satisfy SEC requirements for the incorporation of debt issuance documents into a registration statement.
Investor Verification Checklist
- Verify the total principal amount of the notes issued, which is not specified in this summary text.
- Review the full Underwriting Agreements (Exhibits 1.3 and 1.4) for details on underwriting fees and conditions.
- Examine the Indentures (Exhibits 4.3 and 4.4) for covenants, events of default, and redemption rights.
- Confirm the use of proceeds from this issuance in the associated Form F-3 Registration Statement.